| |
| Novartis Pharmaceuticals UK Ltd Satellite
Session |
| 07.30-08.30 |
Queen's Suite 1 |
|
|
New frontiers in the diagnosis and
management of neuroendocrine tumours |
|
|
|
|
|
|
| British Thyroid Association Pitt-Rivers Lecture |
| 08.30-09.15 |
Main Auditorium Chair: Lazarus J
(Cardiff) |
| S5 |
08.30 |
Essential role of transporters in
cellular entry of thyroid hormone
Visser TJ (Rotterdam, The Netherlands) |
|
|
|
|
|
|
| COFFEE |
|
| 09.15-09.45 |
Hall D |
| |
|
|
|
|
| Symposium 7: The hypothalamic-pituitary-adrenal
axis and inflammation |
| 09.45-11.30 |
Queen's Suite 2 Chair: Simpson ER
(Melbourne, Australia) |
| S28 |
09.45 |
Neuroendocrine and immune changes
associated with autoimmune disease
Harbuz MS (Bristol) |
|
|
|
| S29 |
10.10 |
Structure/function of the glucocorticoid
receptor and its ligands
Ray DW (Manchester) |
|
|
|
| S30 |
10.35 |
Glucocorticoid action in asthma and COPD
Barnes PJ (London) |
|
|
|
| S31 |
11.00 |
Annexin A1 - a unique mediator of
glucocorticoid action
Flower RJ (London) |
|
|
|
|
|
|
| Clinical Management Workshop 3: Endocrine
manipulations in the transsexual |
| 09.45-11.30 |
Queen's Suite 1 Chair: Bouloux P
(London) |
| S44 |
09.45 |
Sexual differentiation of the human brain
and gender
Swaab DF (Amsterdam, The Netherlands) |
|
|
|
| S45 |
10.15 |
Endocrine treatment of the transsexual
Levy A (Bristol) |
|
|
|
| S46 |
10.45 |
Phalloplasty for female to male gender
reassignment
Ralph DJ (London) |
|
|
|
|
|
|
| Oral Communications 5: Thyroid |
| 09.45-11.30 |
King's Suite Chairs: Weetman A
(Sheffield) & Visser TJ (Rotterdam, The Netherlands) |
| OC34 |
09.45 |
Association between serum TSH and fT4
concentrations and occurrence of atrial fibrillation in a large community-based
population of elderly subjects. The Birmingham Elderly Thyroid Study (BETS)
Gammage M, Parle JV, Franklyn JA, Wilson S, Roberts L, Holder R, Sheppard
M, Hobbs FDR, Roalfe A, Heath C & Pattison H |
|
|
|
| OC35 |
10.00 |
Risk of second cancers among people with
thyroid cancer - treatment effects or common aetiology?
Sandeep TC, Strachan MWJ, Reynolds RM, Brewster DH, Scélo G, Pukkala E, Hemminki
K, Anderson A, Tracey E, Friis S, McBride M, Kee-Seng C,
Pompe-Kirn V, Kliewer EV, Tonita JM, Jonasson JG, Martos C, Boffetta P & Brennan
P |
|
|
BRITISH THYROID ASSOCIATION AWARD WINNER |
|
|
|
| OC36 |
10.15 |
PTTG induces genomic instability in
thyroid cells
Kim DS, Stratford AL, Boelaert K, Pemberton H, Gockce C, Eggo M, Tannahill
L, Watkinson JC, Franklyn JA & McCabe CJ |
|
|
|
| OC37 |
10.30 |
PTTG binding factor (PBF) - a novel
transforming gene in thyroid tumorigenesis which represses iodide uptake
Stratford AL, Boelaert K, Tannahill LA, Eggo MC, Gittoes NJ, Franklyn
JA & McCabe
CJ |
|
|
|
| OC38 |
10.45 |
Anti-TNFa therapy inhibits
TNFa-dependent
ICAM1 up-regulation in orbital fibroblasts from patients with thyroid associated
ophthalmopathy
Cawood TJ, Moriarty P, Golden-Mason L, O'Farrelly C & O'Shea D |
|
|
|
| OC39 |
11.00 |
Thyrotrophin receptor (TSHR) activation
in preadipocytes stimulates the early but inhibits the terminal stages of
adipogenesis
Janus D, Baker GRC, Fuhrer D & Ludgate M |
|
|
|
| OC40 |
11.15 |
Development of novel thyroid stimulating
monoclonal antibodies from an experimental model with potencies equivalent
to those in Graves' disease patients, including full agonistic activity
but also differential blocking properties
Gilbert JA, Rao PV, Salehi S, Gora M, McGregor AM & Banga JP |
|
|
BRITISH THYROID ASSOCIATION AWARD WINNER |
|
|
|
|
|
|
| British Thyroid Association Annual General
Meeting |
| 11.30-12.30 |
Main Auditorium |
| |
|
|
|
|
| LUNCH |
|
| 11.30-13.15 |
Hall D |
| |
|
|
|
|
| Attended Posters (odd numbers) |
| 11.30-13.00 |
Hall D |
| |
|
|
|
|
| Moral Maze: Ethics and animal experimentation |
| 13.00-14.15 |
Main Auditorium Chair: Blakemore C
(London) |
|
|
Panel: Coombes B (FRAME) |
|
|
Furr B (AstraZeneca plc) |
|
|
Matfield M (European Biomedical Research
Assocation) |
|
|
|
|
|
|
| Ardana Bioscience Ltd Satellite Session |
| 13.15-14.15 |
Queen's Suite 1 |
|
|
Testosterone replacement: management
across the patient spectrum |
| |
| Symposium 8: Hyperinsulinism-induced
hypoglycaemia |
| 14.15-15.45 |
Queen's Suite 1 Chair: Jones P
(London) |
| S32 |
14.15 |
Hypoglycaemia and the brain
Frier BM (Edinburgh) |
|
|
|
| S33 |
14.45 |
Tumour associated hypoglycaemia -
mechanisms and treatment
Camacho-Hübner C (London) |
|
|
|
| S34 |
15.15 |
Hyperinsulinism in infancy
Dunne M (Manchester) |
|
|
|
|
|
|
| Symposium 9: Regulation of ovarian
folliculogenesis |
| 14.15-15.45 |
Queen's Suite 2 Chair: Franks SJ
(London) |
| S35 |
14.15 |
Dialogue between oocytes and somatic
cells
Eppig JJ (Bar Harbor, USA) |
|
|
|
| S36 |
14.45 |
Anti-mullerian hormone and the dynamics
of follicle development
Themmen APN & Visser JA (Rotterdam, The Netherlands) |
|
|
|
| S37 |
15.15 |
Endocrine and local control of the
preovulatory follicle and developing corpus luteum in primates
Stouffer RL (Beaverton, USA) |
|
|
|
|
|
|
| Clinical Management Workshop 4: Endocrine
sequelae of childhood cancer |
| 14.15-15.45 |
Main Auditorium Chair: Shalet SM
(Manchester) |
| S47 |
14.15 |
Endocrine sequelae of childhood cancer:
overview - size of the problem
Sklar CA (New York, USA) |
|
|
|
| S48 |
14.45 |
Growth and puberty after treatment for
intracranial neoplasia
Spoudeas H (London) |
|
|
|
| S49 |
15.15 |
Ovarian reserve after chemotherapy
Davies M (London) |
|
|
|
|
|
|
| Young Endocrinologists Session: Tricks for
success in research |
| 14.15-15.45 |
King's Suite Chairs: Mostyn A
(Nottingham) & Noon L (London) |
| S54 |
14.15 |
How to survive a PHD
Westwood M (Manchester) |
|
|
|
| S55 |
14.35 |
Career fellowship schemes for the
clinical and non-clinical endocrinologist - where are they and how to succeed
Stewart PM (Birmingham) |
|
|
|
| S56 |
15.00 |
Tricks for success in research: the
clinic versus the lab
Crown AL (Bristol) |
|
|
|
| S57 |
15.25 |
The BTA (been to America) degree: is it
still worth it?
Fowkes RC (London) |
|
|
|
|
|
|
| TEA |
|
|
| 15.45-16.15 |
Hall D |
| |
|
|
|
|
| The Expert's View 7: Science |
| 16.15-17.00 |
Conference Suite Chair: Hewison M
(Birmingham) |
|
|
State of the art lecture: Aquaporins
Verkman A (San Francisco, USA) |
|
|
|
|
|
|
| The Expert's View 8: Clinical |
| GENEROUSLY SUPPORTED BY NOVARTIS
PHARMACEUTICALS UK LTD |
|
|
|
| 16.15-17.00 |
Queen's Suite 1 Chair: Gittoes N
(Birmingham) |
|
|
Diagnosis and management of
neuroendocrine tumours of the pancreas and gut, particularly carcinoids
Grossman A (London) |
|
|
|
|
|
|
| The Expert's View 9: Clinical |
| 16.15-17.00 |
Queen's Suite 2 Chair: Gough S
(Birmingham) |
|
|
Brittle diabetes - does it exist?
Williams G (Bristol) |
|
|
|
|
|
|
| The Expert's View 10: Clinical |
| GENEROUSLY SUPPORTED BY SERVIER
LABORATORIES LTD |
|
|
|
| 16.15-17.00 |
King's Suite Chair: Selby P
(Manchester) |
|
|
Interpretation of bone mineral density
and markers of bone metabolism
Eastell R (Sheffield) |